29 May 2026, Canada: MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow“), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended March 31, 2026. For complete details, please refer to the condensed interim financial statements for the three months ended March 31, 2026, and associated management’s discussion and analysis, available on the Company’s profile at SEDAR+: www.sedarplus.ca or on the Company’s website at: www.mustgrow.ca.
Key Highlights for Q1-2026:
TerraSante sales revenue of $0.1 million in Q1-2026 vs. nil in Q1-2025
TerraSante gross margin of 23.6% in Q1-2026, up from 19.5% in 20251
Expenses from continuing operations2 of $0.9 million in Q1-2026, down from $1.2 million in Q1-2025
Net loss of $1.3 million in Q1-2026, down from $1.6 million in Q1-2025
Cash and equivalents on hand as at March 31, 2026 was $0.4 million, with working capital of $1.5 million
“During the first quarter, our TerraSanteTM contract manufacturers were increasing production capacity to accommodate our forward-looking product requirements, resulting in short-term manufacturing disruptions as production expanded from ‘batch’ production to ‘continuous’ lines dedicated to produce at higher volume rates,” commented Corey Giasson, President and CEO of MustGrow. “These manufacturing disruptions have carried over to the second quarter, however, despite these disruptions, as production capacity for our products increases with our contract manufacturers, so will our ability to execute on timely delivery to meet the growing demand for our products in the U.S.”1
Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com
